FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011614249> ?p ?o ?g. }

• W3011614249 abstract "e20705 Background: Hyponatremia in the cancer patient is usually caused by the syndrome of inappropriate antidiuretic hormone (SIADH). Other factors may cause hypovolemic hyponatremia, diarrhea, and vomiting. It’s present in 47% of cancer admissions. Introduction of vaptans acting as V2-receptor antagonists considerably improved the unconvincing results of conventional treatment consisting of fluid restriction potentially combined with sodium supplementation and/or demeclocycline therapy. Methods: We present a retrospective analysis of hyponatremic cancer patients treated with Tolvaptan. 45 patients, [31 men 14 women], median age 69 years old. 31.1 % had lung cancer, 17,6% other tumors, 11,1% colorectal and 11,1% prostate cancer. Histology: 53,3% Adenocarinoma, 15,6% SCLC, 15,2% others and 5,6% Epidermoid.The mean of the lowest sodium level was associated with squamous histology (Na 118 mEq/L). Descriptively, older patients (>66 y) had lower levels of Na compared to those younger than 66y (Na 122 mEq/L vs Na124 mEq/L). Median of Na at diagnosis of hyponatremia was 124 mEq/L,waiting period days before starting treatment,1d (SD= 1,745). Duration treatment [ Sodium levels out of risk according to the doctor criteria]. Results: Participants improved significantly after treatment period (p=.000). There were no differences in TOLVAPTAN improvements between patients with ≤ 124 mEq/L vs >124 mEq/L (p=.142), but patients with Na ≤ 124 mEq/L tend to achieved higher levels of sodium at the end of treatment (p=.016). No significant differences between different histology, location, waiting period, duration of treatment, or age. However, Men significantly improved after treatment with tolvaptan (p=.000) and women do not showed significant changes (p=.753) (women had significantly higher pretreatment sodium level than men (122.4 mEq/L vs. 126.2 mEq/L,(p= .05). Conclusions: Tolvaptan is effective in the treatment of hyponatremia in patients with differents histological cancers especially with levels lower than 124 mEq/L. Tolvaptan had good safety profile with no side effects. A short course of two days and low dose (15mg/p.o./d ) with Tolvaptan restored safe Sodium levels." @default.
• W3011614249 created "2020-03-23" @default.
• W3011614249 creator A5000149784 @default.
• W3011614249 creator A5004787926 @default.
• W3011614249 creator A5012962517 @default.
• W3011614249 creator A5024328543 @default.
• W3011614249 creator A5046690861 @default.
• W3011614249 creator A5050785789 @default.
• W3011614249 creator A5057527596 @default.
• W3011614249 creator A5066125278 @default.
• W3011614249 creator A5072075286 @default.
• W3011614249 date "2013-05-20" @default.
• W3011614249 modified "2023-09-27" @default.
• W3011614249 title "Hyponatremia and cancer: Results of a retrospective analysis of 45 patients treated with a short course of low-dose tolvapan." @default.
• W3011614249 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e20705" @default.
• W3011614249 hasPublicationYear "2013" @default.
• W3011614249 type Work @default.
• W3011614249 sameAs 3011614249 @default.
• W3011614249 citedByCount "0" @default.
• W3011614249 crossrefType "journal-article" @default.
• W3011614249 hasAuthorship W3011614249A5000149784 @default.
• W3011614249 hasAuthorship W3011614249A5004787926 @default.
• W3011614249 hasAuthorship W3011614249A5012962517 @default.
• W3011614249 hasAuthorship W3011614249A5024328543 @default.
• W3011614249 hasAuthorship W3011614249A5046690861 @default.
• W3011614249 hasAuthorship W3011614249A5050785789 @default.
• W3011614249 hasAuthorship W3011614249A5057527596 @default.
• W3011614249 hasAuthorship W3011614249A5066125278 @default.
• W3011614249 hasAuthorship W3011614249A5072075286 @default.
• W3011614249 hasConcept C121608353 @default.
• W3011614249 hasConcept C126322002 @default.
• W3011614249 hasConcept C143998085 @default.
• W3011614249 hasConcept C167135981 @default.
• W3011614249 hasConcept C2776703092 @default.
• W3011614249 hasConcept C71924100 @default.
• W3011614249 hasConceptScore W3011614249C121608353 @default.
• W3011614249 hasConceptScore W3011614249C126322002 @default.
• W3011614249 hasConceptScore W3011614249C143998085 @default.
• W3011614249 hasConceptScore W3011614249C167135981 @default.
• W3011614249 hasConceptScore W3011614249C2776703092 @default.
• W3011614249 hasConceptScore W3011614249C71924100 @default.
• W3011614249 hasLocation W30116142491 @default.
• W3011614249 hasOpenAccess W3011614249 @default.
• W3011614249 hasPrimaryLocation W30116142491 @default.
• W3011614249 hasRelatedWork W111180878 @default.
• W3011614249 hasRelatedWork W138921007 @default.
• W3011614249 hasRelatedWork W147471764 @default.
• W3011614249 hasRelatedWork W1517493683 @default.
• W3011614249 hasRelatedWork W198304537 @default.
• W3011614249 hasRelatedWork W2261176629 @default.
• W3011614249 hasRelatedWork W2371837510 @default.
• W3011614249 hasRelatedWork W2382775322 @default.
• W3011614249 hasRelatedWork W2593413639 @default.
• W3011614249 hasRelatedWork W2601174134 @default.
• W3011614249 hasRelatedWork W2604550520 @default.
• W3011614249 hasRelatedWork W2782189989 @default.
• W3011614249 hasRelatedWork W2783203600 @default.
• W3011614249 hasRelatedWork W2892848926 @default.
• W3011614249 hasRelatedWork W2969767174 @default.
• W3011614249 hasRelatedWork W3011472366 @default.
• W3011614249 hasRelatedWork W3041821294 @default.
• W3011614249 hasRelatedWork W3047709541 @default.
• W3011614249 hasRelatedWork W3194657945 @default.
• W3011614249 hasRelatedWork W44049170 @default.
• W3011614249 isParatext "false" @default.
• W3011614249 isRetracted "false" @default.
• W3011614249 magId "3011614249" @default.
• W3011614249 workType "article" @default.